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ABSTRACT 
Background and Objectives: Anthracyclines are effective drugs that are widely used in pediatric cancer treatment. 
Previous studies have demonstrated that exposure to low-dose anthracyclines (<300 mg/m
2) induces a progressive 
decrease in cardiac function during long-term follow-up. The goal of this study was to assess left ventricular func-
tion using vector velocity imaging (VVI) in children undergoing low-dose anthracycline therapy. Subjects and 
Methods: We examined 14 asymptomatic patients who had been treated with anthracyclines and had normal frac-
tional shortening (FS) and ejection fraction (EF). In all of the patients, standard two-dimensional (2D) pulsed 
and tissue Doppler echocardiographic measurements were taken from an apical 4-chamber view. The peak myo-
cardial velocity, peak strain rate (SR), peak strain, and displacement were obtained from VVI. Data were compared 
with 14 age-matched healthy controls. Results: From the regional wall motion analysis using VVI in the left ven-
tricle, the peak myocardial velocity and displacement of the lateral wall were increased significantly more than the 
septum, and there were no significant differences between the patients and the controls. Although systolic strain, 
and the systolic and diastolic SRs showed no significant differences between the septum and lateral wall in the con-
trols, those of septum, in the patients, were decreased significantly more than those of lateral wall (p<0.05). In com-
parison with the controls, these changes in septal strain and SRs of patients were significant (p<0.05). Conclusion: 
Anthracycline therapy, even low-dose, can induce changes in regional wall function before global dysfunction. Also, 
the strain and SR obtained from VVI may be useful for early detection of these changes. (Korean Circ J 2009;39: 
352-358) 
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Introduction 
 
With the development of anticancer drugs, radio-
therapy, and the increased opportunity for bone marrow 
or hematopoietic stem cells transplantation, more than 
2/3 of pediatric patients with leukemia or solid tumors 
survive long-term. The side effects following treatment, 
especially acute and chronic cardiac side effects after an-
thracycline infusion, have received considerable atten-
tion.
1)2) Anthracyclines are used in more than one-half 
of the patients who undergo anti-cancer treatment. Re-
cent studies have reported that the changes in cardiac 
function also occur in cases in which the cumulative dose 
of anthracycline is smaller.
3)4) 
The most appropriate method of assessing anti-cancer 
drug-induced cardiotoxicity is echocardiography, which 
can measure cardiotoxicity in a quantitative, non-inva-
sive manner.
5)6) Standard echocardiography assessment 
the global cardiac function. There are limitations with 
the objectivity and accuracy because a gross examination 
is performed in assessment of the motion and dynam-
ics of cardiac tissue, and many environmental factors af-
fect the measurements. The images based on Doppler 
are dependent on the angle of a probe, and only the ve-
locity, the direction of which is the same as a probe, can 
be measured. By contrast, vector velocity imaging (VVI) 
is a newly-developed offline analysis. It detects changes 
in tissue motion at the location which was appointed by 
consecutive two-dimensional (2D)-image frames and 
thereby expresses velocity. It also includes variables in 
which time-dependent differential values are calculated. 
For this reason, in the absence of problems that several 
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previous methods have disclosed, cardiac function can 
be assessed. It has been said that VVI is a superior meth-
od for analyzing tissue strain and strain rate (SR).
7)8) 
In the current study, we performed an analysis of car-
diac function using VVI in patients who did not exhibit 
myocardial symptoms following anti-cancer treatment, 
including anthracyclines. Then, we attempted to iden-
tify the parameters showing changes in the early stage. 
 
Subjects and Methods 
 
Subjects 
Of the patients who received anti-cancer treatment 
following the diagnosis of pediatric cancer at Keimyung 
University Dongsan Medical Center prior to 2005, 14 
patients were enrolled. Their ejection fraction (EF) and 
fraction shortening (FS) were >56% and 29%, respec-
tively, on echocardiography, which was performed on a 
yearly basis while a follow-up observation was contin-
uously conducted until December of 2007. The patients 
consisted of 7 boys and 7 girls with a mean age of 9 years 
and 10 months (range, 6 years and 1 month-17 years 
and 6 months). The diagnoses included seven cases of 
acute lymphoblastic leukemia, three cases of acute mye-
loblastic leukemia, one case of neuroblastoma, two cases 
of non-Hodgkin lymphoma, and one case of Hodgkin 
lymphoma. All of the patients received anthracyclines 
in a protocol for anti-cancer treatment. The cumula-
tive doses were 90-342 mg/m
2. Fourteen aged-matched 
healthy controls were selected.   
The control subjects were referred for evaluation of 
a heart murmur. Because of a lack of abnormal find-
ings, the control subjects were diagnosed with innocent 
murmurs. The control subjects consisted of 9 boys and 
5 girls, with a mean age of 9 years and 11 months (ra-
nge, 7 years-15 years and 4 months). All of the subject 
children had a chest radiograph and an electrocardio-
gram. 
 
Echocardiography 
Echocardiography was performed using an Acuson 
Sequire 512 (Siemens Medical Solution, Mountain View, 
CA, USA) with a 4-MHz transducer. All of the tests that 
were performed were saved on the hard drive and a MO 
disk of the echocardiographic equipment. 
On the parasternal long axis view with the use of M-
mode, the FS, EF, and left ventricular (LV) mass/m
2 were 
measured. 
For diastolic functional analysis, the mitral inflow sig-
nal was acquired in the apical 4-chamber view. The puls-
ed Doppler sample volume was 2 mm and it was placed 
at the mitral valve tip. The early peak flow velocity (E) 
and atrial filling velocity (A) were measured three times 
and averaged, from which the E/A ratio was calculated. 
The time elapsed until the maximal E reached the base-
line, the early filling deceleration time (DT), the time 
elapsed until the mitral valve was opened since aortic va-
lve was closed, and isovolumetric relaxation time (IVRT), 
were measured. 
Tissue Doppler imaging (TDI) measurements were 
performed on the basal septum and mitral annulus. The 
maximal systolic myocardial velocity (S’) and early and 
late diastolic myocardial velocity (E’, A’) were measured. 
At this time, the sample volume was set at 3 mm. The 
time elapsed until the mitral valve was opened since it 
was closed (a’) and the systolic time (b’) were measured. 
The value of (a’-b’) was divided by b’, and the modified 
the modified (MPI) was obtained. 
To analyze the VVI, the ultrasound window of the 
images was controlled in such a manner that the num-
ber of frames was >70 frames per single cardiac beat 
on the apical 4-chamber view and the 2D images were 
acoustically captured. The secured images were saved 
in a MO disk for offline analysis. With the use of an of-
fline analysis program (Syngo US Workplace 3.0, Sim-
ence; Acuson), the contour of endocardium was man-
ually traced on the saved images before the analysis was 
performed. The tracing was performed repeatedly sev-
eral times for the most appropriate endocardial contour. 
In the septum and lateral wall of the LV, the baseline, 
middle part, and apex were subjected to the measure-
ment of maximal velocity, strain, SR, and displacement. 
The contour of endocardium was secured in such a 
manner that the LV was passively drawn. This was con-
firmed by the visual display mode of the velocity im-
ages. 
All of the echocardiographic parameters which were 
obtained for pulsed wave Doppler and TDI were meas-
ured by a single investigator from three cardiac cycles, 
and then averaged. The parameters which were obtained 
from the VVI were the average value from the measure-
ment, which was performed twice. 
 
Statistical analysis 
All the results which were measured using echocar-
diography were expressed as the mean±standard devi-
ation (SD). Statistical analysis was performed using Sta-
tistical Package for Social Science (SPSS) for Windows, 
version 14.0 (SPSS Inc., Chicago, IL, USA). A compar-
ison of echocardiographic measurements in the septum 
and lateral wall of the LV between the patient and con-
trol groups was made with the use of an independent 
t-test. An inter-group analysis was performed using one- 
way analysis of variance (ANOVA), which was followed 
by a post-hoc analysis using Scheffe’s test. A p<0.05 was 
considered statistically significant. 
Parameters of VVI confirmed intraobserver variability. 
The mean difference and 95% confidence intervals be-
tween the first and second measurements were calcu-
lated.  
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Results 
 
Intraobserver variability 
The mean difference and 95% confidence intervals 
of the parameters of VVI are represented in Table 1. 
 
An analysis of cardiac function using 2D and stand-
ard Doppler methods 
There were no significant differences in FS, EF, and 
LV mass/m
2 measured using M-mode between the pa-
tient and control groups. DT and IVRT were longer in 
the patients than the controls but the differences were 
not statistically significant. E, which was measured using 
pulsed wave Doppler, was significantly lower in the 
patients than the controls (p=0.048); however, A and 
E/A did not show a significant difference (Table 2). 
 
An analysis of cardiac function using tissue Doppler 
imaging 
S’, E’, and A’ in the basal septum, and S’ and E’ in the 
lateral mitral annulus, were higher in the patients than 
the controls but this was not statistically significant. By 
contrast, A’ in the lateral mitral annulus was higher in 
the patients than the controls (p=0.027). There was no 
significant difference in E’/A’ between the two groups. 
E/E’ and the modified MPI were all significantly lower 
in the patients {in the basal septum (p=0.031 and p= 
0.037, respectively), and in the lateral mitral annulus (p= 
0.016 and p=0.041, respectively) (Table 3). 
 
An analysis of cardiac function using the vector ve-
locity imaging 
The parameters which were obtained and then aver-
aged from the VVI independent of location, such as 
cardiac velocity in the systolic and diastolic phases, strain, 
and SRs in the systolic and diastolic phases, were higher 
in the controls than the patients; however, there were 
no significant difference in these parameters between 
the two groups (Table 4). 
A comparison of the regional wall functions of the 
ventricular septum and the lateral wall of the LV was 
made, and this revealed a significant difference between 
the patients and the controls (Table 5). In both groups, 
the cardiac velocity in the systolic and diastolic phases 
were lower in the ventricular septum than the lateral wall 
(p<0.001 and p=0.001, respectively). However, there 
were no significant differences between the two groups. 
The strain and SRs in the systolic and diastolic phases 
were not significantly different between the ventricular 
septum and the lateral wall in the controls. In the pa-
tients, however, the strain and SRs in the systolic and di-
astolic phases were lower in the ventricular septum than 
the lateral wall (p<0.001, p=0.011, and p<0.001, respec-
tively). The displacement had a lower value in the ven-
tricular septum in both groups (p=0.006 and p=0.001, 
respectively); however, there was no significant differ-
ence between the two groups. 
In comparison to the lateral wall function of the LV 
between the two groups, it revealed no significant differ-
ence between the two groups. However, in comparison to 
the ventricular septum function between the two groups, 
the SRs in the systolic and diastolic phases were signifi-
cantly lower in the patients (p=0.042 and p=0.010, res-
pectively) (Fig. 1). 
 
Discussion 
 
Anthracyclines are effective drugs that have been fre- 
quently used to treat pediatric patients with leukemias 
or solid tumors, but can produce cardiotoxicity relative 
Table 2. 2D and conventional Doppler echocardiographic parameters of left ventricular function
Patients  Controls   
 
Mean  (SD)  Mean  (SD) 
p 
BSA (m
2)  001.04  00.23  001.09  00.27 0.630 
Heart rate (bpm)  089.00 13.00  091.00 15.00 0.580 
FS (%)  035.16  04.25  036.53  04.68 0.430 
LV mass/BSA (g/m
2)  077.84 16.34  080.78 15.10  0.630 
EF (%)  065.05  05.71  066.68  06.48 0.490 
E (cm/s)  098.29 16.05  110.69 15.62  0.048 
A (cm/s)  051.64 11.94  054.25  07.37 0.510 
E/A  001.99  00.59  002.08  00.45 0.620 
DT (ms)  136.31  21.15  126.62  16.77  0.210 
IVRT (ms)  068.69 11.99  061.62  08.63 0.100 
SD: standard deviation, BSA: body surface area, FS: fractional shortening, EF: ejection fraction, E: peak early diastolic velocity, A: peak late dia-
stolic velocity, DT: early filling deceleration time, IVRT: isovolumetric relaxation time, 2D: two-dimensional, LV: left ventricle   
Table 1. Intra-observer variability of vector velocity imaging param-
eter data 
  Mean difference  95 % CI 
Systolic velocity (cm/s)  0.16  -0.31 to 0.36 
Diastolic velocity (cm/s)  0.21  -0.48 to 0.41 
Strain (%)  0.99  -2.32 to 1.76 
Systolic strain rate (s-1) 0.13  -0.29 to 0.24 
Diastolic strain rate (s-1) 0.18  -0.40 to 0.32 
Displacement (mm)  0.25  -0.47 to 0.57 
CI: confidence interval 
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to the cumulative dose.
1)2) Cardiotoxicity can be divided 
into acute (immediately after treatment), chronic (with-
in 1 year following treatment), and late (>1 year follow-
ing treatment). Higher cumulative doses and more rapid 
rates of drug administration have been shown to lead to 
an increased incidence of late cardiotoxicity.
9) In cases 
in which the period of follow-up observation elapsed 
over 2 years, such echocardiographic findings as FS, the 
thickness of the ventricular wall, and the ventricular di-
mension showed abnormal findings.
10) The proportion 
of pediatric cancer patients who develop cardiotoxicity 
following treatment with anthracycline is 5-10% dur-
ing a mean period of 10 years (range, 2-19 years).
11) Sub-
clinical dysfunction of the LV, which was confirmed us-
ing endomyocardial biopsy, has been reported to be more 
common, with an incidence of 20-75%.
2)9)12) Accord-
ing to recent studies, although the cumulative dose of 
anthracycline was decreased in all the protocols of anti-
cancer treatments using anthracycline, cardiotoxicity 
could not be prevented.
3)4) In pediatric patients, the 
popular methods of diagnosing cardiotoxicity due to an-
thracycline do not include periodic endomyocardial bio-
Table 3. Left ventricular function using tissue Doppler imaging
Patients  Controls   
 
Mean  (SD)  Mean  (SD) 
p 
Septum          
S’ (cm/s)  09.50 0.85 08.96 1.24  0.190 
E’ (cm/s)  16.57  1.50  16.19  2.69  0.640 
A’ (cm/s)  07.86 1.29 07.11 1.84  0.220 
E’/A’  02.17 0.42  02.43 0.75  0.067 
E/E’  05.98 1.09 06.95 1.12  0.031 
Modified MPI  00.36 0.05 00.42 0.09  0.037 
Lateral wall           
S’ (cm/s)  12.93  2.30  11.50 2.31  0.110 
E’ (cm/s)  22.29  3.87  20.41  2.78  0.150 
A’ (cm/s)  08.14 0.95 07.11 1.34  0.027 
E’/A’  02.79 0.65 02.92 0.44  0.082 
E/E’  04.50 0.90 05.38 0.87  0.016 
Modified MPI  00.35 0.05 00.45 0.16  0.041 
SD: standard deviation, S’: peak systolic velocity, E’: peak early diastolic velocity, A’: peak late diastolic velocity, E: peak early diastolic velocity 
in mitral inflow, MPI: mycardial performance index 
 
Table 4. Global function of the left ventricle using vector velocity imaging
Patients  Controls   
 
Mean  (SD)  Mean  (SD) 
p 
Systolic velocity (cm/s)  -03.81 1.04 -04.18 0.81  0.30 
Diastolic velocity (cm/s)  -05.88 1.38 -06.76 1.30  0.10 
Strain (%)  -22.89 2.47 -23.55 4.19  0.61 
Systolic strain rate (s-1)  0-1.75 0.24 0-1.98 0.42  0.09 
Diastolic strain rate (s-1)  -02.63 0.39 0-3.07 0.73  0.06 
Displacement (mm)  -05.70 1.42 0-5.98 0.90  0.54 
SD: standard deviation 
 
Table 5. Regional function of the left ventricle using vector velocity imaging
Patients  Controls 
Septum  Lateral wall  Septum  Lateral wall     
Mean  (SD)  Mean  (SD) 
p 
Mean  (SD)  Mean  (SD) 
p 
Systolic velocity (cm/s)  -03.20  1.93  -04.42  2.46  <0.001  -03.42*  1.87  -04.93 2.14  <0.001 
Diastolic velocity (cm/s)  -05.18.  3.20  -06.58  4.16  <0.001  -05.91*  3.56  -07.61 3.85  <0.001 
Strain (%)  -21.29  4.26  -24.48  6.01  <0.001  -23.38*  5.77  -23.74 5.51  <0.670 
Systolic strain rate (s-1)  0-1.66  0.37  0-1.85  0.47  <0.011  0-1.89*  0.63  0-2.08 0.63  <0.080 
Diastolic strain rate (s-1)  -02.38  0.66  -02.87  0.82  <0.001  -02.96*  1.26  -03.18 1.14  <0.250 
Displacement (mm)  -05.17.  3.39  -06.23  4.03  <0.006  -05.39*  3.26  -06.57 3.17  <0.001 
SD: standard deviation 
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psies or stress echocardiography. For this reason, stand-
ard and Doppler echocardiography, which can be per-
formed repeatedly, are the major diagnostic modalities 
in these cases. 
Previous studies have reported an analysis of cardiac 
function following treatment with anthracycline based 
on echocardiography. It has been reported that a pro-
longed IVRT and an increased MPI following treatment 
with anthracyclines could be effectively used to make a 
diagnosis of cardiac toxicity due to anthracycline.
13-15) Ga-
name et al.
4) analyzed cardiac function 5 years following 
completion of treatment and classified patients in whom 
the cumulative dose was <300 mg/m
2 into a low-dose 
group. Then, the authors noted that all the patients had 
no clinical symptoms and normal EF however, the IVRT 
was prolonged, abnormal pulmonary venous flow pat-
terns developed, the end systolic wall stress was increased, 
the LV annular motion was reduced, and the longitudi-
nal and radial peak systolic SR and strain were decreased 
on the long and short axes. Based on these findings, it 
was concluded that the changes in cardiac function were 
identified in the systolic and diastolic phases. According 
to another study, following anti-cancer treatment using 
anthracycline, myocardial velocity, which was measured 
using a TDI study, showed no significant changes in 
long-term survivors; however, the transmyocardial ve-
locity gradient from the endocardium to the pericardium, 
which can be said to be an indicator of SR, showed a sig-
nificant change in the ventricular septum and posterior 
wall of the ventricle.
16) The changes in cardiac function 
due to the use of anthracycline were initiated from part 
of the myocardium, the degree of which was also very 
small. Therefore, an analysis of the global cardiac funct-
ion did not identify these changes as promptly as pos-
sible. 
In the current study, the cumulative dose of anthra-
cycline was <300 mg/m
2 in 13 patients and >300 mg/m
2 
in 1 patient. All of the patients were clinically asymp-
tomatic and at least 3 years passed since the treatment 
was completed, corresponding to a late phase effect. The 
outcomes that which were observed in these patients 
were as follows: 1) FS and EF were normal. Systolic stra-
in and SR were decreased, and indicating a change in 
cardiac function in the systolic phase. In particular, SR, 
which was measured in the ventricular septum, was low-
er in the patients. This indicated that the regional car-
diac function was decreased during the systolic phase 
in the ventricular septum. 2) Although there was a lack 
of statistical significance, the IVRT was prolonged. A’, 
which was measured on the TDI study, was significantly 
increased and the SR in the diastolic phase was decreas-
ed. These findings indicated that cardiac function was 
also changed during the diastolic phase. The character-
istics of the current study, in which an analysis of car-
diac function was performed using the VVI, were that 
cardiac function was already changed, even in patients 
who were treated with a smaller dose of anthracycline. 
These changes were detected as a change in regional car-
diac function rather than global function. Strain and 
SR, which were measured using the VVI, were chang-
ed to a more significant extent as compared with other 
methods of analyzing cardiac function. 
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Fig. 1. Peak longitudinal function of the septum. Longitudinal function of the ventricular septum was analyzed. There was no significant 
difference in the peak systolic myocardial velocities, strain, and displacement between the control and anthracycline groups (A, B, C). 
But peak systolic and diastolic SR were significantly lower in the anthracycline group compared with the control group (D, E). *p<0.05 
vs. control. SR: strain rate. 
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Methods of measuring regional cardiac function in-
clude TDI, as previously done, and strain and SR. Strain 
is the method of measuring the degree of deformity. It 
is expressed as either the fractional or percent change 
from the unloaded muscle length (the original dimen-
sion) to the loaded muscle length. SR represents the 
strain divided by the time, which is the deformity that 
occurs during a certain length of time. That is, the SR 
represents the rate of deformity. This is used to assess 
cardiac synchrony, cardiac volume, and the functions of 
the left atrium and ventricle.
17)18) The TDI is disadvan-
tageous in that it is affected by the traction exerted by 
the adjacent tissue, as well as the movement of the heart. 
By contrast, the measurement of strain and SR with the 
use of VVI is advantageous in overcoming the disad-
vantages of TDI and measuring the amount and veloc-
ity of regional areas on 2D images both objectively and 
quantitatively. In the current study, there were signifi-
cant changes in E, which was measured using conven-
tional Doppler echocardiography, and A’ and E/E’, 
which were used using the TDI and the modified MPI. 
However, these parameters are significantly dependent 
on the methods of measurement, as well as the cardiac 
loading conditions. The E/E’ and the modified MPI 
were decreased, which was not in agreement with pre-
vious studies,
13-15) indicating that the two parameters 
which were measured using TDI did not accurately re-
flect asymptomatic cardiac dysfunction. By contrast, stra-
in and SR using the VVI, which are not controlled by 
loading as compared with other echocardiographic meth-
ods and overcame several disadvantages, were signifi-
cantly changed in the systolic and diastolic phases. This 
can be interpreted as the usefulness in measuring the 
changes in cardiac function compared to other echocar-
diographic methods. 
When the changes in regional cardiac function were 
observed, the current study and previous study
16) showed 
that the function of ventricular septum was changed 
earlier than that of lateral wall. The causes or mecha-
nisms for this finding are difficult to explain because 
the endomyocardial biopsy was not performed in all 
cases and there were no other testing methods which 
reflected regional cardiac function except echocardiog-
raphy. 
The greatest limitations of the current study were that 
the number of enrolled patients was 14, which is a rel-
atively small number, and it was a cross-sectional study 
in which a comparison was made without baseline data. 
Therefore, it cannot be concluded that the study results 
originated only from the use of anthracycline. Cases in 
which there is a defined difference in cardiac function 
since the diseases were diagnosed, or those in which ra-
diation was performed with the anti-cancer treatment, 
were not excluded out. Secondly, the values of strain and 
SR which generated the significant changes were all with-
in the presumptive normal ranges. This also restricted 
the application of the results to a clinical setting. Fur-
ther, the function of the right ventricle (RV) was not 
analyzed concurrently. Additional studies are warranted 
to examine whether the RV is affected by anthracycline 
to some extent. With the use of radionuclide angiog-
raphy, however, a substantial number of studies have 
shown that the function of the RV were normal fol-
lowing the administration of anthracycline.
19) 
In conclusion, the changes in regional cardiac func-
tion may occur prior to the emergence of changes in 
global cardiac function, even in asymptomatic patients 
who showed normal FS and EF on echocardiography and 
received a low-dose of anthracyclines. The more effec-
tive methods of examining this may be an assessment of 
strain and SR based on 2D images with the use of the 
VVI study. This would be a method of analyzing changes 
in cardiac function as early as possible. To enable a great-
er degree of clinical significance and application, further 
studies are warranted in a larger group of patients with 
long-term follow-up. 
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